Passage Bio Inc
NASDAQCM:PASG
United States / Healthcare / Biotechnology
PASG News
Welcome to Your News Upgrade
Be the First to Know and Act on Market Moving News.
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges
In a turbulent turn of events, Passage Bio Inc (PASG) stock has tumbled to a 52-week low, reaching a distressing price level of $0.38. Despite the decline, InvestingPro data shows...
Chardan cuts Passage Bio stock price target to $6, maintains buy
On Tuesday, Chardan Capital Markets adjusted its price target for Passage Bio Inc . (NASDAQ:PASG) shares, bringing it down to $6.00 from the previous $7.00 while still...
Passage Bio Inc receives Investment Bank Analyst Rating Update
Passage Bio stock plunges to 52-week low of $0.45
In a stark reflection of investor sentiment, Passage Bio Inc (PASG) stock has tumbled to a 52-week low, touching a price level of just $0.45. According to InvestingPro data, the...
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to...
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with...
Passage Bio CFO sells shares worth $1,685
Kathleen Borthwick, the Chief Financial Officer of Passage BIO, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company currently valued at $32.66 million, recently executed...
Passage Bio shares transition to Nasdaq Capital Market
Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market....
Orbimed advisors reduces stake in Passage Bio for $142,223
OrbiMed Advisors LLC, a ten percent owner of Passage BIO, Inc. (NASDAQ:PASG), has reported the sale of a significant portion of its holdings in the company. According to a recent...
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported updated data...